Pages
Blogroll
- Blood Pressure Risk Factors
- Electric mobility scooters
- Hair Growth Product Reviews
- Hoveround Wheelchairs
- Medical Scales
- Mortgage modification trial payments
- NBA Basketball Betting
- Nursing career
- Pancreas Cancer
- Prevent Cancer
- Prostate Cancer Treatment Side Effects
- Type 2 Diabetes Mellitus
Categories
- Cancer Risk
- Cells and Organs
- General Information
- Prostate Help Organizations
- UK Prostate Cancer
- Uncategorized
Archives
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
Meta
The little vaccine maker that could has added a couple of heavyweights to its board of directors.
Dendreon, which hopes to win FDA approval next month for its Provenge prostate cancer vaccine, recruited Ian Clark, a Roche exec who was recently tapped to lead the big drug maker’s Genentech unit (see photo at left), and Pedro Granadillo, who once headed manufacturing at Eli Lilly. Here’s the press release.
The move prompted speculation that Roche, which has a large presence in oncology, could become a bidder for Dendreon. As Reuters notes, Dendreon stock has jumped 10-fold since last spring, when data was released showing Provenge prolonged life for patients by about four months. Meanwhile, Dendreon has been ramping up production and some investors are betting an acquisition may …
Original post by Pharmalot and software by Elliott Back
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.